These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9736582)

  • 1. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents.
    Zhanel GG; Karlowsky JA; Zelenitsky SA; Turik MA; Hoban DJ
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2446-8. PubMed ID: 9736582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
    Pfaller MA; Messer SA; Coffman S
    Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
    Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A
    J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
    Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
    Uzun O; Kocagöz S; Cetinkaya Y; Arikan S; Unal S
    Antimicrob Agents Chemother; 1997 May; 41(5):1156-7. PubMed ID: 9145888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
    Krishnarao TV; Galgiani JN
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1957-60. PubMed ID: 9303393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.
    Karlowsky JA; Harding GA; Zelenitsky SA; Hoban DJ; Kabani A; Balko TV; Turik M; Zhanel GG
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2576-8. PubMed ID: 9371373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans.
    Radding JA; Heidler SA; Turner WW
    Antimicrob Agents Chemother; 1998 May; 42(5):1187-94. PubMed ID: 9593148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
    Klepser ME; Ernst EJ; Ernst ME; Messer SA; Pfaller MA
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1387-91. PubMed ID: 9624481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
    Zhanel GG; Karlowsky JA; Harding GA; Balko TV; Zelenitsky SA; Friesen M; Kabani A; Turik M; Hoban DJ
    Antimicrob Agents Chemother; 1997 Apr; 41(4):863-5. PubMed ID: 9087508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
    Jacobsen MD; Whyte JA; Odds FC
    Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability.
    Green LJ; Marder P; Mann LL; Chio LC; Current WL
    Antimicrob Agents Chemother; 1999 Apr; 43(4):830-5. PubMed ID: 10103187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals.
    Choi HW; Shin JH; Jung SI; Park KH; Cho D; Kee SJ; Shin MG; Suh SP; Ryang DW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1520-3. PubMed ID: 17283191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.
    Jones RN; Kirby JT; Messer SA; Sheehan DJ
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):371-4. PubMed ID: 17376633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
    Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
    J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
    Roling EE; Klepser ME; Wasson A; Lewis RE; Ernst EJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 May; 43(1):13-7. PubMed ID: 12052624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
    Moore CB; Oakley KL; Denning DW
    Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.